Aphorism 发表于 2025-3-25 03:54:58
http://reply.papertrans.cn/83/8285/828458/828458_21.pngpulse-pressure 发表于 2025-3-25 07:57:31
http://reply.papertrans.cn/83/8285/828458/828458_22.pngmitral-valve 发表于 2025-3-25 13:23:09
Proteasome Inhibitors and Lessons Learned from Their Mechanisms of Action and Resistance in Human Cteasomal core as well as factors involved in resistance mechanisms. Further understanding the mechanisms of resistance to proteasome inhibitors in human cancers will significantly improve current proteasome inhibitor therapies and patient care.有助于 发表于 2025-3-25 17:47:24
http://reply.papertrans.cn/83/8285/828458/828458_24.png永久 发表于 2025-3-25 21:18:24
http://reply.papertrans.cn/83/8285/828458/828458_25.png婴儿 发表于 2025-3-26 01:01:55
Proteasome Inhibitors in the Treatment of Multiple Myeloma and AL Amyloidosis,ired, remains a problem in the therapy of clonal plasma cell disorders. This chapter will provide a general overview of the use of PIs in myeloma and AL amyloidosis, with particular emphasis on the limitations of such therapy.Harrowing 发表于 2025-3-26 05:17:26
Profiling Bortezomib Resistance in Multiple Myeloma: Implications in Personalized Pharmacotherapy, treatment or emerging (acquired) resistance where a patient’s tumor cells “acquire” the ability to resist therapy in the course of treatment leading to eventual Bz-resistant relapse. We discuss molecular profiling approaches to characterize bortezomib resistance, including analysis of genomic varia储备 发表于 2025-3-26 09:28:51
http://reply.papertrans.cn/83/8285/828458/828458_28.pngNotify 发表于 2025-3-26 15:17:18
http://reply.papertrans.cn/83/8285/828458/828458_29.png使长胖 发表于 2025-3-26 20:50:23
http://reply.papertrans.cn/83/8285/828458/828458_30.png